The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
Victoria Dzurinko, OD, MBA, FAAO, discusses the opportunity available to improve both patient outcomes and practice bottom lines by integrating dark adaptation testing in the identification and management of AMD.
Due to the impact of AMD on several of his family members, Gary Kirman, OD (of Kirman Eye), has been a staunch advocate of dark adaptation testing as standard of care in eye care practices.
Many older eye care patients elected to defer their visits during the COVID-19 pandemic. That's why Dr. Amanda Legge is using educational and cutting-edge technology, like the AdaptDx Pro, to put their minds at ease.